The aim of this study was to investigate the effects of human β-defensin-3 (hBD3) on intestinal wound healing and in a neonatal rat model of necrotizing enterocolitis (NEC). Methods: Enterocyte migration and proliferation were detected in vitro and in vivo. The role of chemokine receptor CCR6 and its downstream signaling pathway was assessed. Newborn Sprague-Dawley rats were randomly divided into four groups: Control+NS, Control+hBD3, NEC+NS, and NEC+hBD3. Body weight, histological score, survival time, cytokines expression, and mucosal integrity were evaluated. results: hBD3 could stimulate enterocyte migration, but not proliferation, both in cultured enterocytes and in the NEC model. Neutralizing antibody and small interfering RNA confirmed this stimulatory effect was mediated by CCR6. Furthermore, hBD3 induced Rho activation, myosin light chain 2 phosphorylation, and F-actin accumulation. The bactericidal activity of hBD3 was maintained throughout a broad pH range. Strikingly, hBD3 administration decreased the incidence of NEC, increased the survival rate, and reduced the severity of NEC. Moreover, hBD3 reduced the proinflammatory cytokines expression in ileum and serum and preserved the intestinal barrier integrity. conclusion: This study provided evidence that the antimicrobial peptide hBD3 might participate in intestinal wound healing by promoting enterocyte migration and show beneficial effects on newborn rats with NEC.
n ecrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal diseases in premature newborns (1) . Intestinal barrier dysfunction plays an important role in the pathogenesis of NEC. Impaired healing of the damaged mucosa, including epithelial migration and proliferation, has been observed in human and experimental NEC (2, 3) .
Human β-defensin-3 (hBD3, OMIM: 606611), one member of cationic antimicrobial peptides, is inducibly expressed in the epithelium of gut. In addition to the primarily recognized antimicrobial activities, hBD3 also functions as immune modulators linking innate and adaptive immunity (4, 5) . Analysis of intestinal resections obtained from infants with severe NEC revealed that low defensin mRNA and protein expression (6) . Armogida et al. (7) reported that the presence of mediators of the innate immune system in human milk, including hBD3 provided protection for the developing digestive tract of newborns. In addition, defensins induction seemed to be a common and important mechanism of probiotics treatment (8, 9) . Collectively, these studies suggested an important role of defensins in neonatal mucosal defense and intestinal barrier function.
Previous studies revealed the capacity of hBD3 to chemoattract T lymphocytes and CCR6-transfected human embryonic kidney 293 cells through chemokine receptor CCR6, which is also constitutively expressed on human enterocytes (10, 11) . Chemokine ligand CCL20, also known as macrophage inflammatory protein-3α, has been shown to be a unique functional ligand for CCR6. The ligand-receptor pair CCL20-CCR6 plays an important role in gut homeostasis (12) . Thus, CCR6 seems to be able to act as a receptor for both hBD3 and CCL20. Recently, Hirsch et al. (13) reported that hBD3 expression significantly promoted wound healing in Staphylococcus aureusinfected diabetic wounds which were created on the backs of Yorkshire pigs. However, the effect of hBD3 on intestinal wound healing remains unknown to date.
The aim of the current study was to investigate the effects of hBD3 on wound healing in cultured enterocytes and in a well-established rat model of NEC. In this study, we reported that hBD3 could promote migration, but not proliferation, of human and rat intestinal epithelial cells (IECs). Furthermore, we showed that hBD3 treatment could decrease the incidence and severity of NEC, reduce the expression of inflammatory mediators, and protect the intestinal barrier integrity.
RESULTS

hBD3 Promotes IEC Migration
Tris-Tricine gel electrophoresis analysis revealed a single band migrating like a 5-kDa polypeptide (Figure 1a) . And hBD3 exhibited bactericidal activity against clinical isolates Escherichia coli (Figure 1b) and S. aureus (Figure 1c ) in a dose-dependent manner.
No significant cytotoxicity of hBD3 against IEC-6 was observed over a broad range of concentrations and incubation periods as shown in Figure 2a . Comparable results were detected in Caco-2 cells treated with hBD3.
Next, as shown in Figure 2b , cells incubated with hBD3 or CCL20 migrated more than the unstimulated controls, with transforming growth factor-β 1 (TGFβ1) as a positive control. The result was further complimented by a real-time electricalimpedance-based detection method, and the migratory effect was slightly dose dependent (Figure 2c,d) .
To measure the role of hBD3 on enterocyte migration in vivo, we examined the extent of intestinal restitution in a neonatal rat NEC model. The majority of 5-bromo-2′-deoxyuridine (BrdU)-positive cells in control animals had traveled along the villus and even reached the tips (Figure 2e) . On the contrary, most of the staining cells in rats with NEC remained in the crypts (Figure 2f ). Both the distance and extent of intestinal restitution were decreased in NEC rats compared with control animals. The impaired enterocyte migration in NEC was attenuated after hBD3 administration (Figure 2g,i,j) . Taken together, these findings indicate that hBD3 treatment could promote enterocyte migration in vitro and in vivo.
hBD3 Does Not Induce IEC Proliferation
In response to injury, intestinal barrier is re-established by epithelial restitution and proliferation (3, 14) . We next sought to determine the effects of hBD3 on enterocyte proliferation. After a 24-or 48-h incubation, proliferation of enterocytes was not significantly altered by either hBD3 or CCL20 (Figure 3a) . To confirm the results, BrdU incorporation assay and cell cycle analysis were performed. The number of enterocytes labeled with BrdU did not increase significantly after hBD3 or CCL20 treatment when compared with unstimulated controls (Figure 3b) . Data in Figure 3c showed that hBD3 or CCL20 stimulation did not increase the percentage of cells in S phase. However, 10% fetal bovine serum markedly induced enterocyte proliferation.
To define whether hBD3 treatment could induce enterocyte proliferation in vivo, the terminal ileum in each group was immunostained with antiproliferating cell nuclear antigen (PCNA) antibody. The extent of enterocyte proliferation was evidently reduced in animals with NEC (Figure 3d-g ) and was not improved by hBD3 administration (Figure 3d,h) . Together, these data indicate that hBD3 could not induce IEC proliferation in vitro and in vivo.
hBD3 Stimulates Enterocyte Migration via Action on CCR6
hBD3 is known to interact with CCR6 by direct binding (15) . And CCR6, the cognate receptor for ligand CCL20, is expressed by human enterocytes (10, 11) . First, we confirmed the CCR6 expression in Caco-2 and IEC-6 cells by western blot. And the epithelial CCR6 expression was not increased after hBD3 treatment (Figure 4a) . Immunofluorescence staining verified CCR6 localization at the cell surface (Figure 4b ). In addition, as shown in Figure 4c -g, epithelial cells from ileum and colon expressed CCR6 both in newborn and adult rats. However, a reduction of CCR6 expression in neonatal rat was observed when compared with adult rat.
To determine the role of CCR6 in hBD3-stimulated cell migration, neutralizing anti-CCR6 antibody and specific CCR6 small interfering RNA (siRNA) were used to block CCR6 activation. In preliminary experiments, pretreatment with at least 2.5 μg/ml hBD3 for 30 min could significantly decrease the migratory effect of hBD3 (Figure 4h) . As shown in Figure 4i , CCR6 neutralizing antibody, but not control IgG, significantly inhibited hBD3-or CCL20-mediated enterocyte migration. We confirmed that neither CCR6 neutralizing antibody nor control IgG induced cell migration by itself. Moreover, pretreatment with CCR6 neutralizing antibody or control IgG did not reverse the TGFβ1-induced migration.
Next, CCR6 siRNA was transfected in Caco-2 cells, which resulted in a striking reduction in CCR6 expression compared with control siRNA (Figure 4j) . Knockdown of CCR6 prevented further increases in enterocyte migration after subsequent hBD3 treatment (Figure 4k) .
CCR6 is a G-protein-coupled receptor activated mainly via the Gα i subunit. Therefore, we next sought to clarify the It has been reported that Rho-GTP, Rho-associated kinase (ROCK), phospho-myosin light chain 2 (MLC2), and F-actin polymerization were key regulators in cell migration Phosphorylation of MLC2 plays a significant role in the regulation of the assembly of stress fibers (18) . Figure 5d showed that hBD3 treatment increased phosphorylation of MLC2 at serine 19.
Then, we examined the effects of hBD3 on Rho activation. GTP-bound form of Rho increases actin dynamics through regulating the downstream effector ROCK. Of note, hBD3 treatment could increase the formation of activated Rho (Rho-GTP, Figure 5d ,e).
ROCK, a direct effector molecule of RhoA, phosphorylates the myosin binding subunit of myosin phosphatase and inhibits the phosphatase activity (17) . ROCK is also known to directly phosphorylate MLC. Therefore, we last investigated the participation of ROCK in hBD3-induced migration using the selective ROCK inhibitor Y27632. ROCK inhibition resulted in striking reduction of enterocyte migration (Figure 5f ) and F-actin accumulation (Figure 5g) . Taken together, we conclude that hBD3-stimulated enterocyte migration is mediated via a canonical Rho-ROCK signaling pathway and correspondingly increased F-actin accumulation.
hBD3 Reduces the Incidence and Severity of NEC in Rat Model
Because hBD3 was administered via gastric tube, antimicrobial activity of hBD3 was first assessed at pH 1.8, pH 3.2, pH 5.8, and pH 8.5. For both microorganisms, hBD3 activity was maintained throughout a broad pH range. The bactericidal effect of hBD3 was slightly inhibited at pH 8.5 for E. coli, and at pH 5.8 for S. aureus (Figure 6a,b) .
We next sought to determine the physiologic relevance of these findings in the intervention of NEC. Body weight of rats in group NEC+NS gradually decreased throughout the experiment, whereas neonatal rats in group NEC+hBD3 could maintain the body weight during the same period ( Table 1 ). And differences in body weight between NEC+NS and NEC+hBD3 groups became statistically significant at day 4 (P = 0.015). Mother-fed pups showed steady increases in body weight. There were no differences in body weight gain between C+NS and C+hBD3 groups.
Macroscopic and microscopic examination of the gut showed clear evidence of intestinal injury similar to neonatal NEC (Figure 6e-i) . The incidence, survival rate, and histological score in each group were shown in Table 2 . Mother-fed rats did not develop NEC and showed no changes or abnormalities in the small intestinal structure. The incidence of NEC was reduced from 80% (16/20) in group 3 to 50% (12/24) in group 4 (P = 0.039). Mean NEC scores in these two groups were 2.50 and 1.67, respectively (P = 0.01, Figure 6c ). The survival rate (96 h) increased from 25% (5/20) in group 3 to 62.5% (15/24) in group 4 (P < 0.001, Figure 6d) . Administration of hBD3 Many studies have evaluated that the inflammatory cascade is central to NEC process (1,19) . Therefore, we measured cytokines expression in ileum and in serum. There were no differences of all the three cytokines expression between the two mother-fed groups. The ileum mRNA expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-10 were upregulated in the NEC+NS group compared with that in the C+NS group (4.77-, 13.74-, and 3.11-fold increase, respectively). hBD3 treatment decreased these 
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inflammatory mediators mRNA expression in the ileum (P < 0.05, Figure 7a-c) . Next, the effect of hBD3 on the serum concentration of TNF-α was measured by enzyme-linked immunosorbent assay (ELISA). The TNF-α level was significantly higher in NEC rats compared with controls (P < 0.05, Table 3, Figure 7d) . And, hBD3 administration could , or incubated with 5 μg/ml hBD3, 50 ng/ml CCL20, or 1 μg/ml l-α-lysophosphatidic acid. F-actin was stained using phalloidin-fluorescein isothiocyanate (FITC) and analyzed by (a) flow cytometry (representative histogram) and (c) fluorescence microscopy (magnification ×400), n = 5. Bar = 10 μm. (d) MLC2 phosphorylation (Ser19) was increased after hBD3 treatment. Total MLC2 was assessed as a loading control. (d,e) Rho-GTP was induced by hBD3, and total Rho was used as a loading control. Caco-2 cells were pretreated with ROCK inhibitor Y27632 (10 μmol/l). (f) Cell migration and (g) F-actin staining were evaluated respectively, n = 4-5. *P < 0.05 as compared between stimulated and nonstimulated cells. We next investigated the effect of hBD3 on the inflammatory cytokines expression in cultured enterocytes. IEC-6 cells were incubated with various concentrations of hBD3 for 1-24 h, and hBD3 treatment did not induce the mRNA expression of TNF-α (Figure 7e) . Moreover, after incubation with hBD3 for 48 h, the production of TNF-α in supernatants did not increase evidently (Figure 7f) . However, we have observed a slight increase of TNF-α at a higher concentration (25 μg/ml).
To test the effect of hBD3 on the intestinal mucosal integrity, we detected the serum level of diamine oxidase (DAO), an indicator of intestinal injury (20) . Decreased levels of DAO activity were detected in the NEC+NS group (Table 3,  Figure 7g ). And hBD3 treatment increased the concentration of DAO in the serum (P < 0.05). Furthermore, histological expression of tight junction protein zonula occludens-1 (ZO-1) was evaluated. ZO-1 staining was lost in rat pups Statistical significance with P < 0.05 between NEC+NS and NEC+ hBD3 groups.
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exposed to NEC stress when compared with mother-fed pups (Figure 7h-j) . This alteration in ZO-1 was prevented by hBD3 administration (Figure 7k) . Taken together, these data demonstrate that hBD3 decreases the expression of proinflammatory mediators both in ileum and in serum and preserves the intestinal mucosal integrity.
DISCUSSION
The genomic and three-dimensional structural studies provide a convincing evidence for the high degree of conservation among defensins, chemokines, and chemokine receptors.
Comparing of the solution structures of hBD3 and rodent CCL20, the presence of NH 2 -terminal Asp-Cys-Cys-Leu (DCCL) motif is considered to be responsible for their capacity to bind with the same receptor CCR6 (12, 21, 22) . Our data showed CCR6 is widely expressed by epithelial cells in the ileum and colon of neonatal and adult rats. Blockage of CCR6 by neutralizing antibody and specific siRNA verified that hBD3-induced cell migration was mediated by CCR6. In addition, inhibition of the Gα i subunit by PTX resulted in a significantly reduced migratory response without returning to the baseline. The incomplete inhibition suggested that other Figure 7 . Effects of hBD3 on inflammatory cytokines expression and mucosal integrity. Relative mRNA expression of (a) tumor necrosis factor-α (TNF-α), (b) interleukin (IL)-6, and (c) IL-10 in the ileum of rats among four groups was calculated. (d) TNF-α level in the serum was assessed using ELISA. (e) Realtime PCR and (f) ELISA showed the expression of TNF-α in IEC-6 or in the supernatants, respectively. (g) Diamine oxidase (DAO) level in the serum was evaluated. ZO-1 was immunostained on the sections of terminal ileum from (h,i) control and (j,k) necrotizing enterocolitis (NEC) rats that were treated with normal saline (NS) or hBD3 (magnification ×400). Bar = 250 μm. (a-d,g ) n = 12-24, (e,f) n = 3. *P < 0.05 as compared between NEC+NS and NEC+ hBD3 with C+NS. § P < 0.05 between NEC+NS with NEC+ hBD3. Articles signaling molecules may be involved such as phosphoinositide 3-kinase signaling pathway. The active form of Rho family (GTP-bound) regulates actin dynamics and coordinates cell motility. In this study, we showed that hBD3 treatment could stimulate Rho activation and in turn activate its downstream signaling pathway. However, RhoA triggers many target signaling molecules (17) . The effects of hBD3 on other RhoA targets such as mammalian diaphanous formins (mDia1) need further investigation. Furthermore, hBD3 activated different types of cells through alternative pathways, i.e., the G protein and phospholipase C signaling pathway in human keratinocytes (23) and the canonical (p65/RelA) NF-κB signaling pathway in human monocytes (24) .
Previous studies confirmed that the majority of healthy preterm newborns secrete gastric acid in quantity sufficient to maintain the pH value in a range of 3.2-6.5. These changes in pH could affect the bactericidal activity of hBD3 by modifying the peptide or its target. However, our results demonstrated that hBD3 activity was maintained throughout a broad pH range. On the basis of extensive experimental and human investigations, it is clear that multiple risk factors of NEC stimulate the proinflammatory response that ultimately leads to intestinal injury. In addition, inflammatory mediators are known to induce barrier dysfunction (3, 19) . From our study, the expression of inflammatory cytokines, including TNF-α and IL-6, was upregulated in pups with NEC. And the intestinal mucosal integrity was also impaired in NEC rats. Enteral administration of hBD3 decreased the overproduction of proinflammatory cytokines and preserved mucosal integrity, but did not increase anti-inflammatory cytokine IL-10 production. One possible explanation is that the protective effect of hBD3 is not mediated by IL-10.
The molecular mechanisms underlying hBD3 protection are complex. First, compared with hBD1 and hBD2, hBD3 contains significantly more positively charged residues and possesses a stronger bactericidal activity. The bactericidal activity of defensins in vitro does not necessarily imply its ability in vivo. However, findings in knockout mice (matrilysin deficient) suggested that direct pathogen clearance was at least one mechanism of defensin function (25) . Second, antimicrobial peptides, including hBD3, have been shown to demonstrate a biphasic effect, being proinflammatory at higher concentrations, but anti-inflammatory at lower levels (23, 26, 27) . In contrast, our data showed hBD3 did not increase the expression of TNF-α in enterocytes. However, TNF-α production is slightly increased after incubation with a higher concentration of hBD3. Although the exact concentration of hBD3 in intestinal mucosa of newborns is still unknown, studies confirmed that hBD3 peptide was expressed in healthy lower gastrointestinal tract and the expression was selectively increased during inflammation and inflammatory bowel disease (28, 29) . Thus, anti-inflammatory effect of hBD3 may also contribute to its beneficial function. Third, in this study, we introduced a new role of hBD3 in the prevention of NEC via regulation of intestinal restitution. Activation of Rho-ROCK signaling pathway leads to efficient enterocyte migration and intestinal barrier repair in NEC model. Fourth, there is little doubt that intestinal microbes are critically involved in the pathogenesis of NEC. Recent studies suggested defensin also serves to help shape the composition of the colonizing microbiota (30) . It is possible that changes in the microbiota in response to hBD3 administration might be attributed in part to the protective effect. Obviously, there are other important factors within enterocyte itself or in the microenvironment participated in the pathogenesis of NEC. And the effects of hBD3 on these targets and its clinical relevance need further studies.
In summary, the data from our study, for the first time, indicated that hBD3 had protective effects on neonatal rats with NEC via reducing inflammatory mediators, preserving mucosal integrity, and promoting intestinal restitution. Our findings provide evidence that hBD3 functions as a key host defense peptide not only to its bactericidal and chemotactic activity, but also to its induction of wound healing in the gut.
METHODS
Cell Cultures, Reagents, and Antibodies
The Caco-2 (passages 22-28) and IEC-6 (passages 20-28) cell lines were obtained from American Type Culture Collection. Caco-2 was cultured in minimum essential medium supplemented with 10% heat-inactivated fetal bovine serum. IEC-6 was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Recombinant hBD3 (E. coli derived, Prospec, Ness-Ziona, Israel); Recombinant human TGFβ1 and CCL20 (Peprotech, Rocky Hill, NJ); PTX, BrdU, fluorescein isothiocyanate-phalloidin, Y27632, and l-α-lysophosphatidic acid (Sigma, St Louis, MO); Neutralizing anti-CCR6 antibody and IgG control (R&D Systems, Minneapolis, MN); BrdU, PCNA, ZO-1, and CKR-6 primary antibodies (Santa Cruz Biotechnology, Dallas, TX); GAPDH, MLC2, phospho-MLC2, and Rho primary antibodies (Cell Signaling Technology, Beverly, MA); CCR6 siRNA (GenePharma, Shanghai, China).
Antimicrobial Assay
The antimicrobial activity of hBD3 against clinical isolates E. coli and S. aureus was determined using a liquid microdilution assay. Test organisms were provided by Professor Hong Zhang (Children's Hospital of Shanghai). Exponentially growing bacteria were adjusted to a density of 10 7 CFU/ml. Ten microliters of each bacterial suspension was exposed to hBD3 (0-20 μg/ml) in 100 μl sodium phosphate buffer (pH 7.4) and incubated at 37 °C for 2 h. To investigate the effect of acid on hBD3 activity, sodium phosphate buffer was prepared at pH 1.8, pH 3.2, pH 5.8, and pH 8.5. After the incubation period, serial dilutions of the assay culture were prepared and plated in triplicate onto Luria-Bertani broth (Oxoid, Hampshire, UK) plates. The number of colonies was counted the next morning.
Cell Proliferation Assays
Enterocyte proliferation in vitro was measured using Cell Counting Kit-8 (CCK-8, Beyotime, Shanghai, China), BrdU incorporation method, and cell cycle analysis (2, 23) . Ten percentage of fetal bovine serum was used as a positive control. The methodology for quantification of enterocyte proliferation in vivo has been described by Sodhi et al. and Feng and Besner (2, 31) . PCNA-positive cells in the crypts were counted from five high power fields for each segment of intestine.
